A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria:

1. Subjects who understand and voluntarily sign the informed consent form;
2. Male or female subjects ≥ 18 years old;
3. Patients with pathological or cytological evidence of locally advanced orhepatocellular carcinoma, who have failed or are intolerant of previous standardtreatments;
4. At least one measurable lesion judged according to the RECIST version 1.1 standard.
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 (inclusive);
6. Life expectancy ≥ 12 weeks;
7. HLA typing: A-02;
8. Laboratory tests at screening shall meet the following requirements:

• Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;
• Platelet count (PLT) ≥ 90 × 10^9/L;
• Hemoglobin (Hb) ≥ 90 g/L;
• Total bilirubin (TBIL) ≤ 3 × ULN;
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN;
• Blood creatinine (Cr) ≤ 1.5 × ULN or creatinine clearance (calculated based onCockcroft-Gault formula) ≥ 45 mL/min;
• International normalized ratio (INR), prothrombin time (PT), and activatedpartial thromboplastin time (aPTT) ≤ 1.5 × ULN;
• QTc interval (calculated based on Fridericia's formula) ≤ 450 ms for males and ≤ 470 ms for females;

9. For subjects with hepatitis B-related primary hepatocellular carcinoma (HBV-HCC) orhepatitis C-related primary hepatocellular carcinoma (HCV-HCC), those who are with thefollowing conditions are eligible to be enrolled:

• HBV-HCC: resolved HBV infection with concomitant antiviral therapy;
• HCV-HCC: resolved or active HCV infection , where concomitant antiviral therapymay be given for active HCV infection;

9. For patients of childbearing potential (male or female), effective contraceptivemeasures shall be taken during the study treatment and within 3 months after the last dose.For women of childbearing potential, a negative serum/urine HCG test result within 7 daysprior to study enrollment shall be provided.

Exclusion Criteria:

1. Known allergy to any of the components of the investigational product;
2. History of topical treatment with mRNA products or treatment with mRNA vaccines;
3. Patients with a history of major operations within 4 weeks before the first dose, havea plan of major operations during the study (at the investigator's discretion);
4. History of anti-tumor therapies within 4 weeks before the first dose;
5. History of receiving immunosuppressive drugs within 4 weeks before the first dose,except for corticosteroid nasal sprays, inhalants, and systemic prednisone at a doseof ≤ 10 mg/day or similar drugs at equivalent doses;
6. History of organ transplant, bone marrow transplant, or hematopoietic stem celltransplant;
7. History of hemorrhagic diseases such as anaphylactoid purpura, Haemophilia andaplastic anemia;
8. History of live attenuated vaccines within 30 days before the first dose;
9. Central nervous system (CNS) metastases that are symptomatic, untreated, or requirecontinuous treatment;
10. Toxicological events (except alopecia and pigmentation) have not recovered to baselineor NCI-CTCAE v5.0 grade 0-1 after prior anti-tumor therapies;
11. History of autoimmune disorders;
12. History of immediate hypersensitivity, eczema that cannot be controlled by topicalcorticosteroids, or asthma;
13. Uncontrollable concomitant diseases;
14. Active infections currently requiring systemic anti-infective therapy; activepulmonary tuberculosis;
15. Known history of human immunodeficiency virus (HIV) positive or treponema pallidumpositive;
16. Patients with other conditions that are not suitable for participation in the study atthe discretion of the investigator.